A team from the University of Cincinnati, USA, has developed a novel glucagon receptor agonist that has enabled them to examine the action of glucagon. In mice, glucagon receptor agonism resulted in hyperglycaemia and reduced levels of body fat and plasma cholesterol. Activation of the glucagon receptor increased hepatocyte expression and circulating levels of fibroblast growth factor 21. These effects were confirmed in healthy human volunteers, in whom injection of glucagon increased plasma levels of fibroblast growth factor 21.
ORIGINAL RESEARCH PAPER
Habegger, K. M. et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes doi:10.2337/db12-1116
Rights and permissions
About this article
Cite this article
Glucagon control of glucose, energy and lipid metabolism. Nat Rev Endocrinol 9, 131 (2013). https://doi.org/10.1038/nrendo.2013.25
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2013.25